Skip to content

Homoeopathic Treatment for Chronic Migraine Related to Digital Screen Exposure.

Evaluating the Efficacy of Individualized Homeopathic Treatment in Chronic Migraine Associated with Digital Screen Exposure : A Double-Blind, Randomized, Placebo-Controlled Trial. - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/03/105503
Enrollment
60
Registered
2026-03-06
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G437- Chronic migraine without aura

Interventions

Intervention1: Individualised Homoeopathic Intervention : Individualized constitutional Homoeopathic Medicines will be given after proper case taking including the patient s physical, emotional, and m

Sponsors

The Calcutta Homoeopathic Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Adults aged 18-65 years individuals who report using digital screens (computers, phones, or tablets) for a minimum of 4-6 hours per day, on average, for at least 3 months prior to enrolment. 2. Diagnosed with chronic migraine (more than 15 days per month for at least 3 months). 3. Migraine attacks that are moderate or severe (pain intensity greater than 4 on the Visual Analog Scale). 4. Ability to comply with study procedures and attend follow-up visits. 5. Informed consent provided.

Exclusion criteria

Exclusion criteria: 1.Other types of primary headache disorders (e.g., tension headaches, cluster headaches). 2.Severe systemic diseases (e.g., uncontrolled diabetes, hypertension). 3.Previous treatment with homoeopathic remedies in the last 6 months. 4.History of severe psychiatric disorders (e.g., schizophrenia, bipolar disorder). 5.Pregnancy or lactation. 6.Use of abortive or preventive migraine treatments within 1 week of starting the trial. 7.Participation in other clinical trials or use of experimental treatments.

Design outcomes

Primary

MeasureTime frame
Migraine Days: The number of days during which the patient experiences a migraine within the 28 days period (or 4 weeks). This will be assessed weekly using patient diaries. Timepoint: Baseline from week 0 to week 12 will be the primary endpoint.

Secondary

MeasureTime frame
Migraine Disability Assessment (MIDAS)-The change in MIDAS score will be used to measure the impact of treatment on functional disability due to migraines.Timepoint: Baseline at 4 weeks, 8 weeks,12 weeks.

Countries

India

Contacts

Public ContactDr RUPALI BHADURI

The Calcutta Homoeopathic Medical College and Hospital

drrupalibhaduri@gmail.com9571806989

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026